☆ 4.5 Article

Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination

TRENDS IN CARDIOVASCULAR MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Rheumatology

Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic

Mehmet Soy et al.

Summary: Hemophagocytic syndrome (HPS) or hemophagocytic lymphohistiocytosis (HLH) is an acute systemic inflammatory disorder characterized by excessive cytokine production and hyperferritinemia. It can be primary, caused by genetic mutations, or secondary, triggered by underlying disorders like malignancies or infections. In COVID-19 patients, secondary HLH and cytokine storm may lead to severe symptoms such as progressive fever, cytopenia, ARDS, and organ failure. Early differentiation and classification are crucial for appropriate treatment strategies.

RHEUMATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Hematology

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Andreas Greinacher et al.

Summary: The mechanism underlying vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily involves the formation of PF4/vaccine complexes and the proinflammatory environment stimulated by the vaccine, leading to the production of high-titer anti-PF4 antibodies in the body and consequent thrombosis.

BLOOD (2021)

添加到收藏夹

Letter Hematology

Contrast between Prevalence of HIT Antibodies and Confirmed HIT in Hospitalized COVID-19 Patients: A Prospective Study with Clinical Implications

Maxime Delrue et al.

THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Editorial Material Hematology

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Eun-Ju Lee et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Medicine, Research & Experimental

Models for SARS-CoV-2 associated thrombocytopenia associated with hemophagocytic histiocytes

Darrell O. Ricke

Summary: A subset of COVID-19 patients are experiencing secondary immune thrombocytopenia, with very rare cases of vaccine induced prothrombotic immune thrombocytopenia associated with COVID-19 vaccines. Four models proposing the contributions of hemophagocytic histocytes to the etiology of thrombocytopenia associated with SARS-CoV-2 are presented, with one model suggesting potential involvement of hemophagocytic histocytes targeting platelets bound by autoantibodies in COVID-19 VIPIT.

MEDICAL HYPOTHESES (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

In Gratitude for mRNA Vaccines

Elizabeth G. Phimister

Summary: The production of mRNA vaccines against SARS-CoV-2 set a record in 11 months, but the preclinical research behind it spanned decades and faced challenges due to lack of funding. The 2021 Lasker-DeBakey Clinical Medical Research Award was given to Drs. Drew Weissman and Katalin Kariko, pioneer researchers of modified RNA.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Hematology

Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia

Ishac Nazy et al.

Summary: Our study excludes heparin-induced thrombocytopenia in critically ill COVID-19 patients and identifies platelet-activating immune complexes as a novel mechanism contributing to the disease.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

COVID-19 induces a hyperactive phenotype in circulating platelets

Shane P. Comer et al.

Summary: This study found distinct differences in routine full blood count and other clinical laboratory parameters between patients with severe and nonsevere COVID-19. It also determined that all COVID-19 patients possess hyperactive circulating platelets, suggesting abnormal platelet reactivity may contribute to hypercoagulability in COVID-19, influencing the severity of the disease and recovery path complexity.

PLOS BIOLOGY (2021)

添加到收藏夹

Article Hematology

Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond

Emmanuel J. Favaloro et al.

Summary: The article introduces the role and detection methods of the metalloproteinase ADAMTS13 in clinical conditions such as thrombotic thrombocytopenic purpura, as well as discusses the limitations and potential utility of rapid ADAMTS13 testing methods.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

The Use of COVID-19 Vaccines in Patients with SLE

Wei Tang et al.

Summary: This review highlighted the lack of evidence on the safety and efficacy of COVID-19 vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD), with a focus on systemic lupus erythematosus (SLE). Although patients with SLE may have weaker immune responses to the vaccines, there is no significant safety concern associated with vaccination in AIIRD patients. Further studies are needed to determine the optimal vaccination strategies and adjust immunosuppressants accordingly.

CURRENT RHEUMATOLOGY REPORTS (2021)

添加到收藏夹

Article Hematology

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2

Thomas Thiele et al.

Summary: After vaccination with different brands of COVID-19 vaccines, some healthy vaccinees tested positive for anti-PF4/polyanion antibodies, but most of these antibodies did not induce platelet activation. Pathogenic platelet-activating antibodies causing VITT were uncommon after vaccination.

BLOOD (2021)

添加到收藏夹

Article Hematology

Antibody-mediated procoagulant platelets in thrombotic thrombocytopenia

Karina Althaus et al.

Summary: This study reported pathological and immunological findings in eight patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after receiving the ChAdOx1 nCoV-19 vaccine. The results showed that sera from VITT patients contained high-titer antibodies against platelet factor 4 (PF4) and the antibodies induced significant platelet activation leading to an increase in procoagulant markers. The study demonstrated the contribution of antibody-mediated platelet activation in the pathogenesis of VITT.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Immunology

Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection

Dennis McGonagle et al.

Summary: The study explores the involvement of venous immunothrombotic mechanisms in SARS-CoV-2 infection and anti-SARS-CoV-2 DNA vaccination. It suggests that both SARS-CoV-2 infection and DNA vaccines may activate immune responses leading to autoimmunity and thrombosis, particularly in the venous system.

JOURNAL OF AUTOIMMUNITY (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)

Kerry J. Welsh et al.

Summary: This study analyzed VAERS reports of thrombocytopenia after vaccination with Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine. The results showed a reporting rate of 0.80 per million doses for both vaccines, and the observed number of all thrombocytopenia cases following administration of mRNA COVID-19 vaccines is not greater than the number of ITP cases expected. Conclusion: The number of thrombocytopenia cases reported to VAERS does not suggest a safety concern attributable to mRNA COVID-19 vaccines at this time.

VACCINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine

Swathi Sangli et al.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine

Hui Ping Lee et al.

Summary: This report describes a case of immune-mediated thrombotic thrombocytopenic purpura (TTP) diagnosed after administration of the ChAdOx1 nCoV-19 vaccine. Prompt treatment resulted in remission of TTP and discharge of the patient after three weeks.

BMJ CASE REPORTS (2021)

添加到收藏夹

Article Hematology

Anti-Platelet Factor 4 Antibodies Causing VITT do not Cross-React with SARS-CoV-2 Spike Protein

Andreas Greinacher et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

Exacerbation of immune thrombocytopenia following COVID-19 vaccination

David J. Kuter

Summary: A study found that COVID-19 vaccination may have varying effects on ITP patients, with some experiencing significant platelet count drops and new bleeding symptoms post-vaccination, but platelets recovered after rescue treatment.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?

Rossella Talotta et al.

Summary: Antiphospholipid antibodies (aPLs), present in 1-5% of healthy individuals, may play a role in the pathogenesis of rare adverse events following COVID-19 vaccination. These antibodies can activate coagulation factors and induce abnormal platelet activation, potentially leading to thrombotic events. Further investigations are warranted to determine the exact association between aPLs and thrombotic events post-vaccination.

CYTOKINE & GROWTH FACTOR REVIEWS (2021)

添加到收藏夹

Article Clinical Neurology

Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency

Katarzyna Krzywicka et al.

Summary: This study analyzed 213 cases of CVST after COVID-19 vaccination, with distinct clinical profiles between recipients of AstraZeneca/Oxford and mRNA vaccines, including differences in thrombocytopenia and mortality rates.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Hematology

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

Syed Hamza Bin Waqar et al.

Summary: TTP, a rare hematologic threat, has been associated with COVID-19 mRNA vaccines during the COVID-19 pandemic, as seen in a case of a 69-year-old male with multiple comorbidities.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Nicola P. Klein et al.

Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic

Mayte Sanchez van Kammen et al.

Summary: Cases of cerebral venous sinus thrombosis with thrombocytopenia have been reported following vaccination with AstraZeneca/Oxford and Janssen/Johnson & Johnson COVID-19 vaccines. A potential immune-mediated response involving platelet factor 4/heparin antibodies has been suggested as the underlying mechanism. This study found that baseline thrombocytopenia, heparin-induced thrombocytopenia, and platelet factor 4/heparin antibodies were uncommon in patients diagnosed with cerebral venous sinus thrombosis before the COVID-19 pandemic.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Review Clinical Neurology

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review

Maryam Sharifian-Dorche et al.

Summary: CVST and VITT are rare but severe complications following COVID-19 vaccination, with most patients being female. Symptoms typically occur within one week after vaccination, with headache being the primary presenting symptom. Some patients may experience serious complications such as intracerebral hemorrhage.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Article Hematology

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Hannah Maayan et al.

Summary: This study presents a case series of patients who developed acquired Thrombotic Thrombocytopenic Purpura shortly after receiving the BNT162b2 vaccine. It recommends evaluating ADAMTS13 activity in patients with a history of aTTP before and after vaccination, especially with the SARS-CoV-2 vaccine. Close monitoring of patients' clinical situation and laboratory data post-vaccination is essential.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Review Rheumatology

Lupus, vaccinations and COVID-19: What we know now

Alice Mason et al.

Summary: SARS-CoV-2 has caused significant impact on health services, particularly affecting patients with SLE who may be at higher risk of poor outcomes with COVID-19. Multiple vaccines have been authorized temporarily, but concerns remain about their effectiveness in SLE patients, especially those on specific treatments like rituximab or high dose steroids. Further research and data collection are needed to evaluate the impact of vaccination on SLE disease control and the severity of COVID-19 in SLE patients.

LUPUS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia

Angela Huynh et al.

Summary: Alanine-scanning mutagenesis is used to identify the PF4 epitope that is recognized by anti-PF4 antibodies in patients with vaccine-induced immune thrombotic thrombocytopaenia, revealing that the epitope corresponds to the heparin-binding site on PF4. VITT anti-PF4 antibodies show stronger binding response compared to HIT anti-PF4 antibodies, potentially contributing to platelet activation and thrombosis by mimicking the effect of heparin binding on PF4. The findings suggest a potential mechanism for VITT development related to immune complexes formation and platelet activation via Fc gamma receptor IIa.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Sue Pavord et al.

Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Vaccine-Induced Thrombocytopenia with Severe Headache

Farid Salih et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Noam Barda et al.

Summary: The study found that after receiving the BNT162b2 vaccine, most adverse events were not associated with an increased risk, although there was a slight increase in the risk of myocarditis. On the other hand, infection with the Covid-19 virus significantly increased the risk of many serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

Julia Hippisley-Cox et al.

Summary: The study found increased risks of haematological and vascular events leading to hospital admission or death within short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of these events were higher and more prolonged after SARS-CoV-2 infection compared to vaccination in the same population.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Immunology

Antiphospholipid Antibodies and Infection: Non Nova Sed Nove

Savino Sciascia et al.

Summary: The presence of antiphospholipid antibodies in COVID-19 patients may contribute to a pro-coagulant state, but differs from patients with overt APS. Therefore, caution is needed in interpreting and generalizing the role of aPL in the management of COVID-19 patients. Additional well-designed clinical studies are necessary before introducing aPL testing as routine in COVID-19 patients.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Pathogenic Mechanisms of Vaccine-Induced Immune Thrombotic Thrombocytopenia in People Receiving Anti-COVID-19 Adenoviral-Based Vaccines: A Proposal

Bruno Azzarone et al.

Summary: VITT is a rare life-threatening syndrome characterized by thrombotic symptoms and thrombocytopenia, potentially associated with the administration of AVV anti-Covid19 vaccines.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases

Maxime Taquet et al.

Summary: This study found that the incidence of cerebral venous thrombosis and portal vein thrombosis after a COVID-19 diagnosis was significantly higher than in cohorts of individuals who received mRNA vaccines or had influenza.

ECLINICALMEDICINE (2021)

添加到收藏夹

Review Peripheral Vascular Disease

Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management

Marie Hogan et al.

VASCULAR MEDICINE (2020)

添加到收藏夹

Letter Hematology

Heparin induced thrombocytopenia antibodies in Covid-19

Rushad Patell et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

添加到收藏夹

Letter Hematology

Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19

Julien Maquet et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Rheumatology

Antiphospholipid Antibodies in Critically Ill Patients With COVID-19

Meng Xiao et al.

ARTHRITIS & RHEUMATOLOGY (2020)

添加到收藏夹

Editorial Material Hematology

Coagulation abnormalities and thrombosis in patients with COVID-19

Marcel Levi et al.

LANCET HAEMATOLOGY (2020)

添加到收藏夹

Review Hematology

Coagulopathy in COVID-19

Toshiaki Iba et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Review Cell Biology

The coagulopathy, endotheliopathy, and vasculitis of COVID-19

Toshiaki Iba et al.

INFLAMMATION RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 presenting as thrombotic thrombocytopenic purpura (TTP)

Essam Altowyan et al.

BMJ CASE REPORTS (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Thromboembolic Complications in Patients With COVID-19

Gregory Piazza et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Hematology

Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome

Richard R. Riker et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)

添加到收藏夹

Review Critical Care Medicine

The unique characteristics of COVID-19 coagulopathy

Toshiaki Iba et al.

CRITICAL CARE (2020)

添加到收藏夹

Review Medicine, Research & Experimental

SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy

Prasun K. Datta et al.

THERANOSTICS (2020)

添加到收藏夹

Article Hematology

Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and FcγRIIA

R. Palankar et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)

添加到收藏夹

Letter Hematology

Anti-PF4/heparin antibodies are increased in hospitalized patients with bacterial sepsis

Satish Maharaj et al.

THROMBOSIS RESEARCH (2018)

添加到收藏夹

Review Hematology

Autoimmune heparin-induced thrombocytopenia

A. Greinacher et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)

添加到收藏夹

Article Immunology

Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink

Elizabeth R. Vickers et al.

VACCINE (2017)

添加到收藏夹

Review Hematology

Recent advances in diagnostic and therapeutic guidelines for primary and secondary hemophagocytic lymphohistiocytosis

Smita Ramachandran et al.

BLOOD CELLS MOLECULES AND DISEASES (2017)

添加到收藏夹

Review Hematology

Thrombotic thrombocytopenic purpura

Berangere S. Joly et al.

BLOOD (2017)

添加到收藏夹

Article Anesthesiology

A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass

Linda Demma et al.

ANESTHESIA AND ANALGESIA (2012)

添加到收藏夹

Article Immunology

Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990-2008

Emily Jane Woo et al.

VACCINE (2011)

添加到收藏夹

Article Hematology

False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus

R. Pauzner et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)

添加到收藏夹

Article Critical Care Medicine

Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients

JPJ Wester et al.

INTENSIVE CARE MEDICINE (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

Platelet factor 4 neutralizes heparan sulfate-enhanced antithrombin inactivation of factor Xa by preventing interaction(s) of enzyme with polysaccharide

MM Fiore et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.